Analystreport

Nabriva Therapeutics PLC - (NASDAQ: NBRV) had its "buy" rating re-affirmed by analysts at Northland Securities. They now have a $12.50 price target on the stock.

Nabriva Therapeutics plc - Ordinary Shares  (NBRV) 
Last nabriva therapeutics plc - ordinary shares earnings: 3/12 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.nabriva.com/investor-relations